Argenx Se (ARGX) — 6-K Filings

All 6-K filings from Argenx Se. Browse 42 Foreign Current Report reports with AI-powered summaries and risk analysis.

6-K Filings (42)

6-K Filing — Apr 20, 2026
Argenx SE Files December 2025 6-K Report — Dec 15, 2025 Risk: low
Argenx SE filed a Form 6-K on December 15, 2025, reporting for the month of December 2025. The company, a biopharmaceutical firm specializing in biological prod
6-K Filing — Nov 18, 2025
Argenx SE Files 6-K Report — Oct 30, 2025 Risk: low
Argenx SE filed a Form 6-K on October 30, 2025, reporting for the period ending September 30, 2025. The filing is a report of a foreign private issuer and inclu
Argenx SE Files 6-K Report — Oct 29, 2025 Risk: low
Argenx SE filed a Form 6-K on October 29, 2025, reporting as a foreign private issuer. The filing provides information for the month of October 2025 and indicat
Argenx SE Files October 2025 6-K Report — Oct 15, 2025 Risk: low
Argenx SE filed a Form 6-K on October 15, 2025, reporting information for the month of October 2025. The filing is from their principal executive offices locate
Argenx SE Files October 2025 6-K Report — Oct 3, 2025 Risk: low
Argenx SE filed a Form 6-K on October 3, 2025, reporting for the month of October 2025. The filing is from a foreign private issuer and is submitted under Rule
Argenx SE Files August 2025 6-K Report — Aug 25, 2025 Risk: low
Argenx SE filed a Form 6-K on August 25, 2025, reporting for the month of August 2025. The company, a foreign private issuer, is based in Zwijnaarde, Belgium, a
arGEN-X SE Files 6-K with H1 2025 Financials — Jul 31, 2025 Risk: low
On July 31, 2025, arGEN-X SE filed a 6-K report for the period ending June 30, 2025. The filing includes financial data for the first half of 2025 and the full
argenx SE Files Form 6-K — Jun 30, 2025 Risk: low
On June 30, 2025, argenx SE issued a press release. The filing is a Form 6-K, which is a report of a foreign private issuer. The company's principal executive o
argenX SE Files Form 6-K with SEC — Jun 20, 2025 Risk: low
On June 20, 2025, argenx SE announced the issuance of a press release. The filing is a Form 6-K, which is a report of a foreign private issuer submitted to the
argenx SE Q1 2025 Results: Revenue Soars, Net Loss Narrows — Jun 11, 2025 Risk: medium
On June 10, 2025, argenx SE announced the publication of its first quarter 2025 financial results. The company reported total revenue of $178.1 million for Q1 2
argenx SE Q1 2025 Results & Business Update — May 28, 2025 Risk: medium
On May 28, 2025, argenx SE announced the publication of its first quarter 2025 financial results and provided a business update. The company reported total reve
argenx SE Files Form 6-K for Q1 2025 Reporting — May 8, 2025 Risk: low
On May 8, 2025, argenx SE filed a Form 6-K, reporting information for the period ending March 31, 2025. The filing includes details about the company's operatio
Argenx SE Files Form 6-K with SEC — Apr 28, 2025 Risk: low
On April 28, 2025, argenx SE announced the issuance of a press release. The filing is a Form 6-K, which is a report of a foreign private issuer submitted to the
argenx SE Announces Annual General Meeting — Apr 14, 2025 Risk: low
On April 11, 2025, argenx SE announced its upcoming annual general meeting. The company, a biopharmaceutical firm focused on autoimmune diseases, is based in Zw
argenx Q1 2025 Results Show Strong Revenue Growth — Apr 11, 2025 Risk: medium
On April 10, 2025, argenx SE issued a press release announcing its first quarter 2025 financial results. The company reported total revenue of $1.2 billion for
argenX SE Files April 2025 6-K Report — Apr 8, 2025 Risk: low
On April 8, 2025, argenx SE filed a Form 6-K with the SEC. This report is for the month of April 2025 and is filed by a foreign private issuer. The company's pr
Argenx SE Files 6-K Report — Mar 7, 2025 Risk: low
On March 7, 2025, argenx SE filed a Form 6-K, reporting its status as a foreign private issuer. The filing provides information regarding the company's principa
argenx SE Files February 2025 Form 6-K — Feb 27, 2025 Risk: low
On February 27, 2025, argenx SE filed a Form 6-K report. This filing is for the month of February 2025 and pertains to the period ending December 31, 2024. The
argenx to Present at J.P. Morgan Healthcare Conference — Jan 13, 2025 Risk: low
On January 13, 2025, argenx SE announced its participation in the upcoming 43rd Annual J.P. Morgan Healthcare Conference. The company will present on January 15
argenX SE Files Form 6-K for December 2024 — Dec 27, 2024 Risk: low
On December 27, 2024, argenx SE announced the issuance of a press release. This filing is a Form 6-K report of a foreign private issuer, indicating it is provid
argenx SE Files November 2024 Report on Form 6-K — Nov 20, 2024 Risk: low
On November 20, 2024, argenx SE filed a Form 6-K, reporting its activities for the month of November 2024. The filing is a report of a foreign private issuer pu
argenx SE Q3 2024 Results Show Strong Revenue Growth — Nov 12, 2024 Risk: medium
On November 11, 2024, argenx SE announced the publication of its third quarter 2024 financial results. The company reported total revenue of $220.5 million for
argenx SE Files October 2024 6-K Report — Oct 31, 2024 Risk: low
On October 31, 2024, argenx SE filed a Form 6-K, reporting on its activities for the month of October 2024. The filing is a report of a foreign private issuer a
argenx SE Files 6-K Report — Oct 15, 2024 Risk: low
On October 15, 2024, argenx SE issued a press release to report on its business and financial updates. The company, headquartered in Amsterdam, the Netherlands,
Argenx SE Files 6-K Report — Sep 19, 2024 Risk: low
On September 19, 2024, argenx SE filed a Form 6-K, reporting its status as a foreign private issuer. The filing provides information regarding its principal exe
Argenx SE Files Routine 6-K Report — Jul 25, 2024 Risk: low
Argenx SE filed a Form 6-K on July 25, 2024, reporting its financial and operational status as of June 30, 2024. The filing is a routine report for foreign priv
argenx SE Reports Q2 2024 Results and Business Update — Jul 16, 2024 Risk: medium
On July 16, 2024, argenx SE announced the publication of its second quarter 2024 financial results and provided a business update. The company highlighted progr
argenx SE Closes $1 Billion Convertible Notes Offering — Jun 25, 2024 Risk: medium
On June 25, 2024, argenx SE announced the closing of its previously announced offering of 0% convertible senior notes due 2031, raising approximately $1.0 billi
argenx SE raises $1.465 billion in stock and notes offering — Jun 24, 2024 Risk: medium
On June 21, 2024, argenx SE announced the closing of its previously announced offering of 1,500,000 ordinary shares at a price of $310.00 per share, resulting i
argenx SE raises over $2.5B from share and note offerings — Jun 17, 2024 Risk: medium
On June 17, 2024, argenx SE announced the closing of its previously announced offering of 1,725,000 ordinary shares at a price of $315.00 per share, resulting i
argenx SE Q1 2024 Results Show Strong Revenue Growth — May 9, 2024 Risk: medium
On May 9, 2024, argenx SE announced its first quarter 2024 financial results. The company reported total revenue of $332 million, a significant increase driven
argenX SE Announces AGM Voting Results — May 8, 2024 Risk: low
On May 7, 2024, argenx SE announced the voting results from its Annual General Meeting of Shareholders held on May 7, 2024. Key resolutions included the reappoi
argenx SE Q1 2024 Update and Financial Results — Apr 16, 2024 Risk: medium
On April 16, 2024, argenx SE announced the publication of its first quarter 2024 financial results and provided a business update. The company highlighted its p
argenx SE Announces Annual General Meeting Details — Mar 27, 2024 Risk: low
On March 26, 2024, argenx SE announced a convocation notice for its upcoming Annual General Meeting of Shareholders. The meeting is scheduled to take place on A
argenx SE Reports Strong 2023 Financials and Pipeline Progress — Mar 26, 2024 Risk: medium
On March 26, 2024, argenx SE announced the publication of its fourth quarter and full year 2023 results. The company reported total revenue of €1.2 billion for
arGENX SE Files March 2024 Report (6-K) — Mar 21, 2024 Risk: low
On March 21, 2024, arGENX SE filed a Form 6-K, reporting information for the month of March 2024. The filing indicates arGENX SE is a foreign private issuer and
argenx SE Reports Q4 and FY 2023 Results — Mar 8, 2024 Risk: medium
On March 7, 2024, argenx SE announced the publication of its fourth quarter and full year 2023 results. The company reported strong financial performance and pr
ARGENX SE Files 6-K for Press Release and Investor Presentation — Feb 29, 2024 Risk: low
ARGENX SE, a foreign private issuer, filed a Form 6-K on February 29, 2024, to report the issuance of a press release and an investor presentation. The company,
ARGENX SE Files 6-K for February 2024 Press Release — Feb 20, 2024 Risk: low
ARGENX SE, a foreign private issuer, filed a Form 6-K on February 20, 2024, to report the issuance of a press release on the same date. The company, with Commis
ARGENX SE ANNOUNCES VYVDURA APPROVAL VIA 6-K FILING — Jan 18, 2024
On January 18, 2024, argenx SE announced the approval of VYVDURA, a significant development for the company. This 6-K filing indicates that argenx SE issued a p

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX